We’re Drs. Winston Tan and John “Al” Copland and we collaborate in pursuit of cures for kidney cancer. Winston is a Mayo Clinic physician oncologist who treats kidney cancer patients and collaborates with Al, a Mayo scientist dedicated to kidney cancer research.
In talking with kidney cancer survivors and friends, we have been encouraged to begin a blog about our research efforts and discoveries in kidney cancer. Current FDA approved drugs are not cures. They provide some survival benefit (in a small number of cases, long term). These treatments not only have a number of toxicities issues but also do not work permanently for patients. Thus, new therapies are desperately needed. In pursuit of new treatments, we have discovered new cancer genes (from the greater than 22,000 genes expressed in human body) that may lead to new treatments for kidney cancer and for other cancers where these genes occur. So much is still unknown for every cancer but we now have the technologies including genomic and functional genomic techniques to make impactful discoveries.
Today, we are introducing our blog series with new insights and discoveries into new genes and treatment options for kidney and related cancers. We will discuss with you cutting edge discoveries and share our struggles along the way as we make new discoveries. Join us in this new adventure as an interactive learning process. We all can participate together in asking and answering questions as well as bring new cutting edge data to this forum. We encourage you to post news & links of discoveries from around the world to this blog. Together, we’ll gain a better understanding of kidney cancer, cancer biology and move forward towards cures.
Our laboratory has several technologies and capabilities that allow us to link clinical observations to functional cancer biology that may lead to new drugs to treat multiple cancers.
- Technologies to examine gene and protein expression in patients’ tumor tissues.
- Patient derived cell lines – originating from surgically resected tumor tissues
- shRNA technology – silence a gene and determine if that gene in a patient’s cells promotes tumor growth and metastasis
- In silico drug screening and drug synthesis allowing us to develop new compounds that may become tomorrow’s drugs.
- Cell based and in vitro models to test compound specificity.
Thus, we can determine if a gene is elevated in a patient’s cancer tissue. If it is, we can test the cell line (developed from that patient’s tumor tissue) by silencing the gene. We then determine if the cells grow slower, don’t survive or don’t metastasize. If any of one of these three is true, then the gene is an important target to consider developing a drug that blocks its cancer promoting activity. Thus, using these step-wise methods allows us to validate many important new cancer genes.
We have discovered over 30 new genes in kidney cancer that promote tumor growth. We recently published one of these genes, SCD1. We showed an SCD1 inhibitor leads to massive cell death and it can be combined with an FDA approved drug, temsirolimus leading to greater cell death. In our next blog, we will share our thoughts on developing this combination therapy for clinical trials. And later, we will share with you discoveries of a second gene from the 30 plus genes. This gene is as exciting as SCD1 having never been described before as a cancer gene! You can see that we much to share from our laboratory discoveries on new gene targets along with insights to patient care from Winston and other topics that you may suggest important to our conversation.
We do envision that our discoveries will benefit other cancers. We know that SCD1 is over expressed in many cancers along with our second discovered gene. We have access to different types of cancer tumor tissues. From these tumor tissues, we develop patient tumor derived cell lines in the laboratory for breast, ovarian, prostate, bladder, brain, head & neck, lung, pancreatic and colon cancers as well as melanoma. We will examine these cancer cell lines for antitumor activity and share our results with you. Thus, we can test our gene discoveries for benefit against other cancers. In our next blog, we will also share with you other cancers that are growth inhibited by SCD1.
So, come on the journey with us. We hope to inspire and educate one another along the way to solving some deadly mysteries. Like a detective, we have some very exciting leads but don’t know where they will ultimately lead us or if we will solve the ultimate crime -death by cancer- and catch the gang members (genes gone bad). We have to go for it! Did you know that over 1.665 million Americans will be told “You have cancer” in 2014. About 585,720 Americans will die this year. There is 545,600 minutes in a year. Think about this – 3 people every minute will become a cancer victim and one person every minute will be die in the U.S.A. On the world stage, 2014 estimated new cancer diagnoses will be 1,665,540 made and cancer deaths will be 1,333,249 (http://www.medindia.net/patients/calculators/world_cancer_clock.asp). This calculates to 11.8 deaths per minute around the world. The need is urgent. We are called to action.